Screener / SEC EDGAR /CIK 0001759655 /10-K filed Feb 27, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Health Services

Privia Health Group, Inc. PRVA

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of PRVA's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter Apr 4, 2023
Questions asked 36 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 4 UPLOAD
  2. 2. Questions in them 36 numbered comments
  3. 3. Company replies 6 CORRESP
  4. 4. Reviews closed 1 of 2 closing letter

Half the closed reviews took 15 days or less from the first letter to the closing letter.

Form 10-K for the Fiscal Year Ended December 31, 2022

2023-04-04 to 2023-04-19 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2023-04-19
Non-GAAP measuresKey metrics
Key Metrics and Non-GAAP Financial Measures, page 72
SEC asked
In future filings, please revise to reconcile the non-GAAP measures "Care Margin" and "Platform Contribution" to the most comparable GAAP measure, which appears to be Gross Profit, even if it is not presented on the face of the Statements of Operations. Please also revise the similar reconciliation in Exhibit 99.1 to your Form 8-K dated February 28, 2023.
PRVA answered
The Company will revise its future filings with the Commission, beginning with its Form 10-Q and corresponding earnings release for the first quarter of 2023, to reconcile these measures to Gross Profit as the most comparable GAAP measure. For illustrative purposes, the Company will include the following reconciliations in future quarters:

For the Three Months Ended March 31,

(Dollars in Thousands) 2023 2022

Revenue $ — $ —

Provider expense — —

Amortization of intangible assets — —

Gross Profit $ — $ —

Care Margin $ — $ —

Cost of Platform — —

Stock compensation (included in cost of
Rest of the answer

platform) — —

Platform Contribution $ — $ —

Care Margin

We define Care Margin as Gross Profit excluding amortization of intangible assets. Gross profit is defined as total revenue less provider expenses and amortization of intangible assets.

Platform Contribution

We define Platform Contribution as Gross Profit, excluding amortization of intangible assets, less Cost of platform and excluding stock-based compensation expense included in Cost of platform.

The reconciliation of Care Margin and Platform Contribution that begin on page 72 in our Form 10-K dated December 31, 2023, is revised as follows:

For the Years Ended December 31,

(Dollars in Thousands) 2022 2021 2020

Revenue $ 1,356,660 $ 966,220 $ 817,075

Provider expense 1,051,040 727,827 629,487

Amortization of intangible assets 3,351 1,312 642

Gross Profit $ 302,269 $ 237,081 $ 186,946

Care Margin $ 305,620 $ 238,393 $ 187,588

Cost of Platform (170,838) (174,731) (105,006)

Stock compensation (included in cost of platform) 13,758 43,888 —

Platform Contribution $ 148,540 $ 107,550 $ 82,582

Our reconciliation in Exhibit 99.1 to our Form 8-K dated February 28, 2023, is revised as follows:

For the Three Months Ended December 31, For the Years Ended December 31,

2022 2021 2022 2021

(Dollars in Thousands) Unaudited

Read in the reply
In its next report

First report after the company's reply of Apr 17, 2023: 10-Q filed May 4, 2023 ↗, against the 10-Q filed Nov 10, 2022 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2023-04-19

Form S-1

2021-01-22 to 2021-04-26 · 35 questions · 3 letters from the SEC, 5 from the company
No closing letter
RevenueRisk factorsNon-GAAP measuresLiquidity and cashLegal and contingenciesKey metricsResults discussion (MD&A)ChinaDebt
SEC letter of Jan 22, 2021 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
DRS S-1 filed December 28, 2020 · Cover Page
SEC asked (1)
We note that you indicate in your graphic that you have generated $1.3 billion in practice collections. Please disclose your revenues and net income (loss) figures here with equal prominence. Please also explain how practice collections correspond to revenues. Prospectus Summary, page 1
PRVA answered

No reply letter found.

DRS S-1 filed December 28, 2020 · Cover Page
SEC asked (2)
Here, at page 81, page 101, and anywhere else you deem appropriate, please revise your disclosure to state succinctly and in plain-English your business structure and operating model. In this discussion, specifically state what products and services you provide and how they generate revenue.
PRVA answered

No reply letter found.

DRS S-1 filed December 28, 2020 · Cover Page
SEC asked (3)
Please provide a corporate structure chart of your operations. In this chart, please indicate what entities (or group of entities) you own and those with which you have a contractual relationship.
PRVA answered

No reply letter found.

DRS S-1 filed December 28, 2020 · Cover Page
SEC asked (4)
Please disclose in your Prospectus Summary, and anywhere else you deem appropriate, the breakdown of how your revenue is generated. Disclose whether the revenue is generated from owned entities or contractual relationships.
PRVA answered

No reply letter found.

DRS S-1 filed December 28, 2020 · Cover Page
SEC asked (5)
We note that you identify a total addressable market of over $3 trillion in annual U.S. healthcare spend. Please disclose what portion of this amount represents the type of services you provide to your customers.
PRVA answered

No reply letter found.

DRS S-1 filed December 28, 2020 · Cover Page
SEC asked (6)
You state throughout your filing that "as of the twelve months ended September 30, 2020, approximately $1.3 billion total practice collections, high return on invested capital with superior unit economics and high free cash flow conversion." Please discuss why you chose this 12 month period given that your fiscal year ends on December 31 and that you are omitting interim financials for the period ending September
Rest of the question

30, 2019 and 2020. If you believe that you should continue to use this period, please provide disclosures for a similar period (i.e., 12 months) ending on September 30, 2019 for comparison.

PRVA answered

No reply letter found.

DRS S-1 filed December 28, 2020 · Cover Page
SEC asked (7)
Please provide a summary of the competitors in your marketspace.
PRVA answered

No reply letter found.

Technology and Population Health, page 7
SEC asked (8)
Please modify your graphic here to ensure that all text is legible. Please make such adjustments throughout your filing as necessary.
PRVA answered

No reply letter found.

Risk Factors, page 14
SEC asked (9)
Please disclose here that you will be a "controlled company" and the implications of that designation. If our current agreements or arrangements with any of our majority-owned medical groups are deemed invalid under state law, page 34
PRVA answered

No reply letter found.

Risk Factors, page 14
SEC asked (10)
To the extent material, please summarize in your Business section, or where you deem appropriate, the referenced agreements and arrangements with your majority-owned medical groups. Please attach as exhibits any such arrangements. Our certificate of incorporation will designate the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, page 66
PRVA answered

No reply letter found.

Risk Factors, page 14
SEC asked (11)
We note that your amended and restated bylaws will provide that the Court of Chancery of the State of Delaware is the exclusive forum for certain claims. You also state that this provision "will not apply to suits to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction." Please ensure that your amended and restated
Rest of the question

bylaws reflects this language. Use of Proceeds, page 70

PRVA answered

No reply letter found.

Risk Factors, page 14
SEC asked (12)
If known, please revise your Use of Proceeds section to disclose the amounts that will be allocated to the purposes referenced.
PRVA answered

No reply letter found.

Non-GAAP Financial Measures, page 77
SEC asked (13)
Please revise, throughout the filing, to present the most directly comparable GAAP measure with equal or greater prominence whenever you present a non-GAAP financial measure. Refer to Question 102.10 of the Compliance & Disclosure Interpretations-Non- GAAP Financial Measures.
PRVA answered

No reply letter found.

Selected Consolidated Financial Data · Key Metrics, page 77
SEC asked (14)
We note that your key metrics include both owned and affiliated medical groups. Since it appears that your owned and affiliated medical groups contributed to significantly different revenue sources, please explain to us your consideration of separately disclosing owned and affiliated medical groups for each of your metrics.
PRVA answered

No reply letter found.

Key Factors Affecting Our Performance, page 85
SEC asked (15)
Please expand your disclosure to discuss how you define the market from which you derive your market share.
PRVA answered

No reply letter found.

Comparison of the Year Ended December 31, 2019 and 2018 · Revenue, page 92
SEC asked (16)
Please revise to disclose your revenue by specific sources as indicated on page F-20 and provide a discussion of significant variances and related drivers for each revenue source. In that regard, we note that your FFS-patient care revenue and FFS-administrative services revenue were driven by different groups of implemented providers. Refer to the requirements of Item 303(a) of Regulation S-K.
PRVA answered

No reply letter found.

Governance and Physician Leadership Culture, page 117
SEC asked (17)
Please provide more details on your multipurpose governance model, including any specific duties and authority to make corporate policies. Please discuss any ability of the company's management to override any decisions.
PRVA answered

No reply letter found.

Case Studies, page 122
SEC asked (18)
Please provide a summary of why you are including "case studies" and what they are meant to convey. Please explain why you selected the profiled clients and how these clients provide a meaningful representation of your customer base.
PRVA answered

No reply letter found.

Government Regulations, page 128
SEC asked (19)
We note that you operate in six states and the District of Columbia. We also note that you are subject to multiple state and federal regulations, some of which prohibit you from practicing medicine, controlling physicians’ medical decisions or engaging in practices such as splitting fees with physicians. Please expand your disclosure to identify the states in which you generate material revenue.
Rest of the question

Please discuss how the state laws in these states apply to your business, including your corporate structure and contractual arrangements. Revise your disclosures throughout, where appropriate, to account for this information.

PRVA answered

No reply letter found.

Certain Relationships and Related Party Transactions, page 149
SEC asked (20)
We note that your Lead Sponsors will control you following the offering. We also note that your Lead Sponsors include investment entities affiliated with Goldman Sachs, one of your underwriters in this offering. Please discuss the underwriting arrangements here if it qualifies as a related party transaction.
PRVA answered

No reply letter found.

Forum Selection, page 156
SEC asked (21)
Please revise to include disclosure in this section that the forum selection provision will not apply to suits to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.
PRVA answered

No reply letter found.

Note 1. Organization and Summary of Significant Accounting Policies · Organization, page F-7
SEC asked (22)
Please revise to disclose your accounting treatment for the 51% owned Privia Management Services Organization joint venture.
PRVA answered

No reply letter found.

Note 1. Organization and Summary of Significant Accounting Policies · Organization, page F-7
SEC asked (23)
You disclose here that the medical groups that are majority-owned by you (owned medical groups) reflect their operations within your consolidated financial results and that they have no ownership in the underlying physician practices.
Rest of the question

You also disclose on page F-12 that your FFS-patient care revenue is generated from providing healthcare services to patients through affiliated physician practices that are members of your consolidated medical groups. Please respond to the following: • Please clearly disclose the relationship between the owned medical groups and their membered physician practices, including the revenue sources of the owned medical groups and the physician practices and the related accounting treatment. • Since you consolidate the owned medical groups but not the membered physician practices (because they are not owned), please provide us your analysis of your basis for reporting related revenues on a gross basis under ASC 606-10-55-36 to -40.

PRVA answered

No reply letter found.

Variable Interest Entities, page F-8
SEC asked (24)
You disclose here that your affiliated physician practices and your non-owned medical groups are not considered to be VIEs and thus not consolidated in your financial statements. Please respond to the following: • Please clarify for us, and revise if necessary, whether the affiliated physician practices referenced here also include the affiliated physician practices that are members of your consolidated medical
Rest of the question

groups. If not, please revise here and throughout the filing to clearly distinguish affiliated physicians practices with your owned and non-owned medical groups. • Please describe to us, and revise if necessary, the relationship and responsibilities between you and your non-owned medical groups and their affiliated physician practices, including the service agreements, and billing and payment arrangements. • Please clarify for us the difference in your agreements with those physician practices who are members of your consolidated medical group and those affiliated physician practices of your non-owned medical group. Also, clarify for us how those differences impacted your revenue recognition.

PRVA answered

No reply letter found.

Revenue Recognition, page F-12
SEC asked (25)
Please revise to clarify the reason that the adoption of ASC 606 resulted in a reclassification of bad debt expense from general and administrative expense to a contra revenue account.
PRVA answered

No reply letter found.

Revenue Recognition, page F-12
SEC asked (26)
Please expand to further disclose details of all variable consideration for FFS–patient care as well as for other revenue sources. Clarify the nature of implicit price concessions, discounts or other reductions and the methods, inputs and assumptions used in determining the related transaction price in accordance with ASC 606-10-50-20.
Rest of the question

We note that you disclosed rebates under certain management services agreements on page 131.

PRVA answered

No reply letter found.

Note 8. Note Payable, page F-23
SEC asked (27)
We note your disclosure that interest expense relating to the note payable is included in general and administrative expenses in your consolidated statements of operations. Please explain to us why this is not included in interest expense.
PRVA answered

No reply letter found.

Exhibits
SEC asked (28)
Please list and attach all material agreements, including, but not limited to, employment agreements, compensation arrangements, and services agreements.
PRVA answered

No reply letter found.

General
SEC asked (29)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
PRVA answered

No reply letter found.

SEC letter of Mar 1, 2021 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
DRS S-1 Amendment #1 filed February 16, 2021 · Prospectus Summary, page 1
SEC asked (1)
We note your response to our prior comment 4 and reissue it in part. Please disclose the revenue and net income (loss) generated by your owned subsidiaries and the same for your non-owned affiliates.
PRVA answered

No reply letter found.

DRS S-1 Amendment #1 filed February 16, 2021 · Prospectus Summary, page 1
SEC asked (2)
We note your response to our prior comment 7 and reissue it in part. Please include in your Prospectus Summary an overview of the competitive landscape. Expand your Risk Factors summary as necessary to include this information.
PRVA answered

No reply letter found.

Technology and Population Health, page 7
SEC asked (3)
We note your response to our prior comment 8 and reissue it. Please modify your graphic here to ensure that all text is legible. Please make such adjustments throughout your filing as necessary.
PRVA answered

No reply letter found.

Case Studies, page 123
SEC asked (4)
We note your response to our prior comment 18. Please revise your disclosure to include the substance of your response.
PRVA answered

No reply letter found.

Note 1. Organization and Summary of Significant Accounting Policies · Revenue Recogntion, page F-13
SEC asked (5)
We note your revised disclosures for the principal or agent consideration with respect to FFS-patient care revenue. Please explain to us, and revise if necessary, how you have considered the risk of loss in your analysis, including the following: • How you structure your compensation arrangements with physicians associated with your owned medical groups, who are also the minority owners of these medical groups.
Rest of the question

In that regard, we note the disclosure that you set reimbursement rates and physician and practice expense consists primarily of physician guarantee payments and costs to run the practices that provide medical services and this expense is typically a percentage of revenue or fixed cost based on a range of revenue. • Who bears the risk of loss related to payments from governmental, commercial or patient payers. • Who is responsible for any losses at the physician practices.

PRVA answered

No reply letter found.

The Offering, page 20
SEC asked
You have disclosed that the number of shares of common stock to be outstanding following this offering excludes 684,887 shares of common stock, plus future increases, reserved for future issuance under your Second Amended and Restated Stock Option Plan as of December 31, 2020.
Rest of the question

Please revise to disclose here, and in the capitalization and dilution sections, the number of your outstanding stock options, their weighted average exercise price per share, and their vesting conditions expected at the offering. In that regard, we note your board of directors recently approved a modification that accelerate the vesting of certain outstanding stock options.

PRVA answered
In response to the

Staff’s request, the Company has updated its disclosure on pages 22, 79 and 81.
Read in the reply

Also in this review: company letter, Apr 14, 2021, company letter, Apr 21, 2021, company letter, Apr 26, 2021, company letter, Apr 26, 2021

Letters without questions

Other letters

UPLOAD and CORRESP
3 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like
  • Nov 16, 2021 · PRVA: letter to the SEC · Privia Health Group, Inc. · Registration Statement on Form S-1 · Registration No....
  • Nov 16, 2021 · PRVA: letter to the SEC · Privia Health Group, Inc. Registration Statement on Form S-1, as amended (File No....
  • Jul 29, 2021 · SEC: letter · Privia Health Group, Inc. · Draft Registration Statement on Form S-1 · Submitted July...

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 14 letters filed since 2021-01-22. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PRVA/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.